Clinical Trial Update: Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing Rituximab plus standard CHOP versus Rituximab plus bi-weekly CHOP in untreated stage III/IV low-grade B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Haruhiko Fukuda | Conditions: Lymphoma, B-Cell | Phase 2, Phase 3 | Status: COMPLETED